Abstract:figure legend This study investigated two rare cystic fibrosis transmembrane conductance regulator (CFTR) variants, S1159F and S1159P, which affect the same amino acid in CFTR by breaking a hydrogen bond (dotted line) with D979, that are associated with different disease phenotypes. S1159P appears to be associated with residual exocrine pancreatic function (pancreatic sufficiency) and S1159F with loss of exocrine pancreatic function (pancreatic insufficiency). Using single‐channel recording in cell‐free membrane patches (the dotted lines indicate where channels are closed and downward deflections correspond to channel openings), both rare variants modestly reduced current flow through CFTR, but markedly inhibited channel gating with S1159F causing the severer impact, which correlates with its disease phenotype. Thus, detailed CFTR investigations explain phenotypic differences, informing treatment with CFTR‐targeted therapies. Some residues in the cystic fibrosis transmembrane conductance regulator (CFTR) channel are the site of more than one CFTR variant that cause cystic fibrosis. Here, we investigated the function of S1159F and S1159P, two variants associated with different clinical phenotypes, which affect the same pore‐lining residue in transmembrane segment 12 that are both strongly potentiated by ivacaftor when expressed in CFBE41o− bronchial epithelial cells. To study the single‐channel behaviour of CFTR, we applied the patch‐clamp technique to Chinese hamster ovary cells heterologously expressing CFTR variants incubated at 27°C to enhance channel residence at the plasma membrane. S1159F‐ and S1159P‐CFTR formed Cl− channels activated by cAMP‐dependent phosphorylation and gated by ATP that exhibited thermostability at 37°C. Both variants modestly reduced the single‐channel conductance of CFTR. By severely attenuating channel gating, S1159F‐ and S1159P‐CFTR reduced the open probability (Po) of wild‐type CFTR by ≥75% at ATP (1 mM); S1159F‐CFTR caused the greater decrease in Po consistent with its more severe clinical phenotype. Ivacaftor (10–100 nM) doubled the Po of both CFTR variants without restoring Po values to wild‐type levels, but concomitantly, ivacaftor decreased current flow through open channels. For S1159F‐CFTR, the reduction of current flow was marked at high (supersaturated) ivacaftor concentrations (0.5–1 μM) and voltage‐independent, identifying an additional detrimental action of elevated ivacaftor concentrations. In conclusion, S1159F and S1159P are gating variants, which also affect CFTR processing and conduction, but not stability, necessitating the use of combinations of CFTR modulators to optimally restore their channel activity. Key points Dysfunction of the ion channel cystic fibrosis transmembrane conductance regulator (CFTR) causes the genetic disease cystic fibrosis (CF). This study investigated two rare pathogenic CFTR variants, S1159F and S1159P, which affect the same amino acid in CFTR, to understand the molecular basis of disease and response to the CFTR‐targeted therapy ivacaftor. Both rare variants diminished CFTR function by modestly reducing current flow through the channel and severely inhibiting ATP‐dependent channel gating with S1159F exerting the stronger adverse effect, which correlates with its association with more severe disease. Ivacaftor potentiated channel gating by both rare variants without restoring their activity to wild‐type levels, but concurrently reduced current flow through open channels, particularly those of S1159F‐CFTR. Our data demonstrate that S1159F and S1159P cause CFTR dysfunction by multiple mechanisms that require combinations of CFTR‐targeted therapies to fully restore channel function.

The Solute Carrier Family 26 Member 9 Is a Modifier of the Rapidly Progressing Cystic Fibrosis Associated with F508del CFTR Mutations

The solute carrier family 26 member 9 modifies rapidly progressing cystic fibrosis associated with homozygous F508del CFTR mutation

Consistent Assignment of Risk and Benign Allele at rs2303153 in the CF Modifier Gene SCNN1B in Three Independent F508del- CFTR Homozygous Patient Populations

The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9

Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci

SFPQ rescues F508del-CFTR expression and function in cystic fibrosis bronchial epithelial cells

Estimation of Chloride Channel Residual Function and Assessment of Targeted Drugs Efficiency in the Presence of a Complex Allele [L467F;F508del] in the CFTR Gene

Single-cell RNA-Sequencing Co-Expression Analysis with CFTR in Lung Tissue

Functional Consequences of CFTR Interactions in Cystic Fibrosis

Modifier genes in cystic fibrosis-related liver disease

Targeting F508del-CFTR to Develop Rational New Therapies for Cystic Fibrosis

S2599 A Rare Cystic Fibrosis Gene Mutation Associated With GI Manifestations in the Absence of Pulmonary Disease

Impact of Gene Modifiers on Cystic Fibrosis Phenotypic Profiles: A Systematic Review

CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation

Unity Is Strength: The Mutual Alliance between CFTR and SLC26A6 as Therapeutic Opportunity in Cystic Fibrosis

Genomic Rearrangements in the Cftr Gene: Extensive Allelic Heterogeneity and Diverse Mutational Mechanisms

Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia

F508del-CFTR rescue: a matter of cell stress response

Two rare variants that affect the same amino acid in CFTR have distinct responses to ivacaftor

Compound heterozygous CFTR variants (Q1352H and 5T; TG13) in a Chinese patient with cystic fibrosis

Structural Insights into the Gating Mechanism of Human SLC26A9 Mediated by Its C-terminal Sequence